

Pneumonia: diagnosis and management (update) Committee meeting 6

Date: 20/06/2024

Location: Virtual

Minutes: Final

Committee members present:	
Tessa Lewis (Chair)	Present for notes 1 – 9
Sumiah Al-Azeib	Present for notes 1 – 9
Srini Bandi	Present for notes 1 – 9
Tom Bewick	Present for notes 1 – 9
Dan Furmedge	Present for notes 1 – 9
Alastair Hay	Present for notes 1 – 9
Saira Hague	Present for notes 2 – 4, part of 5, 6 onwards
Jennifer Head	Present for notes 1 – 9
Philip Howard	Present for notes 1 – 4, part of 5
Marisa Lanzman	Present for notes 1 – 9
Paddy McMaster	Present for notes 1 – 9
Mitul Patel	Present for notes 1 – 9
Carole Pitkeathley	Present for notes 1 – 5
Kathryn Thomas	Present for notes 1 – 9
Alan Thomas	Present for notes 6 onwards
Avril Tucker	Present for notes 1 – 9
Martin Williams	Present for notes 1 – 2, part of 3 & 5, 6 onwards
Caroline Ward	Present for notes 1 – 5
Dan Wootton	Present for notes 1 – 9

In attendance:		
Steph Armstrong	Senior Health Economist	Present for notes 1 – 9
Chris Carmona	Topic Lead	Present for notes 1 – 9
Chris Harris	Project Manager	Present for notes 1 – 9
Cheryl Hookway	Implementation Manager	Present for notes 2 – 5,

		part of 6, 8 onwards
Joanna Perkin	Senior Medical Editor	Present for notes 1 – 9
Edgar Masanga	Business Analyst – Resource Impact Assessment, NICE	Present for notes 1 – 9
Robby Richey	Topic Lead	Present for notes 1 – 9
Eric Slade	Health Economics Adviser, NICE	Present for notes 6 onwards
Hannah Stockton	Technical Analyst	Present for notes 1 – 5
Rachel Walsh	Technical Analyst, NICE	Present for notes 1 – 9

Apologies:

Dan Horner	Consultant in Emergency Medicine & Intensive Care
Joy Okafor	Advanced Clinical Practitioner
Paul Levay	Information Specialist, NICE
Michellie Young	Technical Analyst, NICE

1. Welcome and introductions

The Chair welcomed Committee members and attendees to the sixth meeting on Pneumonia: diagnosis and management (update). The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above. The minutes of the previous meeting were confirmed as a true and accurate record.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was diagnosis and management of pneumonia. The Chair noted several previously declared interests which will be kept under review.

The Chair asked everyone to verbally declare any new interests. The new interests declared are outlined below:

Name	Job title	Declarations of Interest, date declared	Type of interest	Decision taken
------	-----------	-----------------------------------------	------------------	----------------

Philip Howard	Pharmacist	Author: cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study Journal of Antimicrobial Chemotherapy Oxford Academic (oup.com)	Non-financial, Professional and personal interest	Non specific Declare and participate Rationale: COVID-19 is excluded from the scope for the update.
Paddy McMaster	Consultant in Paediatric Infectious diseases	Hospital lead for BATCH study procalcitonin in suspected infection in children Biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: statistical analysis plan for the BATCH trial and PRECISE sub-study - PubMed (nih.gov)	Non-financial, Professional and personal interest	Non specific Declare and participate Rationale: not specific to pneumonia

The Chair and a senior member of the Developer's team noted that these and no other previously declared interests would prevent attendees from fully participating in the meeting.

2. Non-invasive ventilation discussion

The Chair introduced Chris Carmona, Technical Adviser who took the committee through a short presentation on non-invasive ventilation. A discussion followed.

3. 4 & 5. Review Question 4.1: In people in hospital with a diagnosis of community- or hospital-acquired pneumonia, what is the clinical and cost effectiveness of monitoring C-reactive protein or procalcitonin and other biomarkers (or combinations of biomarkers) in addition to clinical observation in helping to determine when to deescalate or change treatment and when to change the place of care (for example, from ICU to non-ICU care or discharge from hospital)?

**Any outstanding matters for adults clinical evidence
Presentation of children's clinical evidence**

The Chair introduced Hannah Stockton, Technical Analyst who presented the committee with evidence relating to biomarkers for de-escalation of care. The committee asked questions, discussed the evidence presented and drafted

recommendations.

6 & 7. Review Question 4.2: What are the most effective and cost-effective microbiological tests or combination of tests at presentation in secondary care to inform treatment decisions in people with suspected community-acquired pneumonia or suspected hospital-acquired pneumonia?

Presentation of clinical and health economic evidence

The Chair introduced Chris Carmona Topic Advisor and Steph Armstrong, Senior Health Economist who presented clinical and health economic evidence on microbiological tests in secondary care to inform treatment decisions. The committee discussed the evidence and drafted recommendations. The Chair thanked Chris and Steph for their presentation and the committee for their contributions.

8. Health economic modelling discussion

The Chair introduced Steph Armstrong, Senior Health Economist who took the committee through the options for health economic modelling. The committee discussed these and asked questions.

9. AOB and next steps

There was no other business. Chris Harris, Project Manager, outlined the next steps for the committee and gave a brief reminder on future meetings and timelines. The Chair thanked those present and closed the meeting.

Date of next meeting: 24/07/2024

Location of next meeting: Virtual